Evaluation of Short Versus Long Courses of Antibiotics in Critically Ill Patients With Gram-Negative Bloodstream Infections
- PMID: 38347703
- PMCID: PMC11317549
- DOI: 10.1177/10600280241231611
Evaluation of Short Versus Long Courses of Antibiotics in Critically Ill Patients With Gram-Negative Bloodstream Infections
Abstract
Background: Short courses of antibiotics (7-10 days) are effective for uncomplicated gram-negative bloodstream infections (GN-BSI). However, prior studies have been limited to small cohorts of critically ill patients.
Objective: The objective of this study was to evaluate the safety and efficacy of short courses of therapy compared with longer courses in patients admitted to the intensive care unit (ICU) with GN-BSI.
Methods: Propensity-matched, retrospective cohort study of critically ill patients with GN-BSI. The primary outcome was a composite of 30-day mortality or 60-day relapse. Secondary endpoints were components of the composite, 30-day relapse, cure with or without adverse drug events (ADE), and ADEs. Regression analysis was performed to identify factors predictive of the composite outcome.
Results: 225 patients were included in the propensity analysis, 145 in the long cohort and 80 in the short cohort. The primary outcome occurred in 3.8% of patients in the short group and 9.0% of patients in the long group (P = 0.24). There was no difference in 30-day mortality (3.8% vs 5.5%, P = 0.79), 60-day relapse (0% vs 3.4%, P = 0.23), or 30-day readmission (20% vs 22.8%, P = 0.76). ADEs were more common in the long group (47.2% vs 34.1%, OR 1.7, 95% CI 1.04-2.9), primarily attributable to diarrhea.
Conclusion and relevance: In critically ill patients with GN-BSI, there were no efficacy outcome differences in patients treated with a short course of antibiotics compared with longer. However, patients in the short group were less likely to experience ADE. These findings suggest that short courses of antibiotics are effective for GN-BSI in critically ill patients.
Keywords: antimicrobial stewardship; bacteremia; drug resistance; durations of therapy; intensive care unit; microbial.
Conflict of interest statement
Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
The Effectiveness and Safety of the Short-Course Therapy in Liver Transplant Recipients With Uncomplicated Gram-Negative Bacteremia: A Retrospective Study.Transpl Infect Dis. 2025 Jan-Feb;27(1):e14434. doi: 10.1111/tid.14434. Epub 2024 Dec 28. Transpl Infect Dis. 2025. PMID: 39731650
-
Extended-Infusion β-Lactam Therapy, Mortality, and Subsequent Antibiotic Resistance Among Hospitalized Adults With Gram-Negative Bloodstream Infections.JAMA Netw Open. 2024 Jul 1;7(7):e2418234. doi: 10.1001/jamanetworkopen.2024.18234. JAMA Netw Open. 2024. PMID: 38954416 Free PMC article.
-
Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections.Infection. 2017 Oct;45(5):613-620. doi: 10.1007/s15010-017-1020-5. Epub 2017 May 6. Infection. 2017. PMID: 28478600
-
Short-course versus long-course antibiotic treatment in patients with uncomplicated gram-negative bacteremia: A systematic review and meta-analysis.J Clin Pharm Ther. 2021 Feb;46(1):173-180. doi: 10.1111/jcpt.13277. Epub 2020 Sep 27. J Clin Pharm Ther. 2021. PMID: 32981149 Free PMC article.
-
Empirical decision-making for antimicrobial therapy in critically ill patients.BJA Educ. 2023 Dec;23(12):480-487. doi: 10.1016/j.bjae.2023.09.001. Epub 2023 Oct 19. BJA Educ. 2023. PMID: 38009140 Free PMC article. Review. No abstract available.
References
-
- CDC.COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. U.S. Department of Health and Human Services, CDC; 2022. doi:10.15620/cdc:117915 - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical